$147.340
+4.700 (+3.19%)Zum Schluss
BLTE-News
BLTE-Events
Belite Bio Submits Marketing Authorization Applications for Tinlarebant
Belite Bio announced marketing authorization application, or MAA, submissions to the regulatory authorities in Singapore, the United Kingdom, and Switzerland for tinlarebant in the treatment of Stargardt disease type 1, or STGD1. Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. There are currently no approved treatment options for the disease in Singapore, the United Kingdom, or Switzerland. The three MAAs have been submitted via the Access Consortium framework in an agreement by the Health Sciences Authority, Medicines and Healthcare products Regulatory Agency and Swissmedic. These MAA submissions in addition to NDA submissions in the U.S. with Priority Review and Japan under the Sakigake Designation System for accelerated review, support Belite's mission of building a global footprint for tinlarebant for STGD1 worldwide.
Belite Bio Submits New Drug Application in Japan
Belite Bio announced the submission of a New Drug Application to the Ministry of Health, Labour, and Welfare in Japan for tinlarebant in Stargardt disease type 1. Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 9,500 people in Japan alone, and there are currently no approved treatment options for the disease. Tinlarebant has been designated a SAKIGAKE pharmaceutical product for accelerated review and the NDA in Japan was filed side-by-side with the United States NDA to enable simultaneous early access for patients in both regions. Tinlarebant will be reviewed under the Sakigake Designation System - Japan's expedited regulatory pathway for innovative medical products. If approved, it could become the first Sakigake pharmaceutical product for ophthalmology disease in Japan.
Stock Futures Modestly Higher, Cerebras Systems Down 15%
Stock futures are modestly higher as investors digest softer-than-feared Producer Price Index data that follows yesterday's July CPI report.The Fed outlook has become somewhat more favorable for equities following the inflation data and the weak July employment report. Markets are now pricing roughly a 66% probability that the Fed holds rates steady at its next meeting, according to Reuters.Technology and AI infrastructure stocks remain an important source of strength. At the same time, Cerebras Systems is under pressure after its results missed expectations, highlighting how high expectations have become for companies tied to the AI buildout.Oil prices are providing some relief after six consecutive sessions of gains. Brent crude has fallen roughly 2% as concerns over global demand and rising U.S. crude inventories offset continued geopolitical risks surrounding Iran and the Strait of Hormuz.In pre-market trading, S&P 500 futures rose 0.17%, Nasdaq futures fell 0.02% and Dow futures rose 0.30%.Check out this morning's top movers from around Wall Street, compiled by The Fly.UP AFTER EARNINGS -Jack in the Boxup 15%EnerSysup 14%Birkenstockup 12%Grocery Outletup 9%McGraw Hillup 3%BK Technologiesup 2%Red Robinup 2%Belite Bioup 1%DOWN AFTER EARNINGS -Cerebras Systemsdown 15%Tapestrydown 10%Yetidown 9%Intuitive Machinesdown 9%Ciscodown 7%Coherentdown 6%JD,comdown 3%Bending Spoonsdown 2%
Belite Bio Receives FDA Priority Review
As of June 30, the company had $279.9M in cash and cash equivalents, compared with $352.9M on December 31, 2025. "We continue to make significant strides in advancing tinlarebant in Stargardt disease. The FDA's acceptance of our NDA is a pivotal milestone for Belite Bio and the STGD1 community, bringing us meaningfully closer to potentially delivering the first ever approved treatment for STGD1. We believe the Priority Review status reflects the strength of our data and recognizes the tremendous unmet need for people living with this debilitating retinal disease," said Dr. Tom Lin, Chairman and Chief Executive Officer of Belite Bio. "Simultaneously, our launch preparations are well underway, including continuing our team expansion and building out our commercial and operational infrastructures. We believe we will be well positioned for both a strong launch and long-term success."
Belite Bio's Tinlarebant Receives FDA Priority Review
Belite Bio announced that the FDA has accepted and granted Priority Review designation of the NDA for tinlarebant for the treatment of Stargardt Disease Type 1. The FDA has set a PDUFA date of February 12, 2027. The filing was based on the results from the Phase 3 DRAGON trial, which evaluated tinlarebant for the treatment of STGD1. In the study, tinlarebant demonstrated a statistically significant and clinically meaningful 35.7% reduction in the growth rate of atrophic retinal lesions, measured as definitely decreased autofluorescence by fundus autofluorescence imaging, compared with placebo. If approved, tinlarebant would be the first ever FDA-approved treatment option for STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss and affects an estimated 53,000 people in the U.S. alone.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.